Business Insider

FDA Clears Xavant Technology's Stimpod NMS460 Non-Invasive Neuromodulation Device for Treatment of Chronic Intractable Pain

PRETORIA, South Africa, Aug. 1, 2017 /PRNewswire/ -- Xavant Technology (Pty) Ltd today announced that the U.S. Food and Drug Administration (FDA) cleared their Stimpod NMS460. With the U.S. patent ...
News Medical

Xavant Technology's neuromodulation device receives FDA clearance for treatment of chronic intractable pain

Xavant Technology (Pty) Ltd today announced that the U.S. Food and Drug Administration (FDA) cleared their Stimpod NMS460. With the U.S. patent awarded on proprietary hybrid pulsed radio frequency ...
Medscape

FDA Clears Noninvasive Device for Intractable Pain

The US Food and Drug Administration (FDA) has cleared a noninvasive neuromodulation device (Stimpod NMS460, Xavant Technology) for the relief of chronic intractable pain, the company has announced.
Monthly Prescribing Reference

FDA Clears Non-Invasive Device to Treat Chronic Intractable Pain

The Stimpod NMS460 includes a nerve-mapping pen-like probe which allows practitioners to locate nerves and evaluate the treatment progress. Xavant Technology announced that their non-invasive ...
Business Insider

Revolutionary Neuromodulation Technology Confirmed as Effective Treatment for Diabetic Neuropathy in Interim Study Results

PRETORIA, South Africa, May 14, 2018 /PRNewswire/ -- Xavant Technology (Pty) Ltd today announced its attendance at the upcoming 11 th Diabetologists Conference, which will be held in New York from May ...